Study: NCT02599090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total of 60 Gy delivered over 30 Days (approximately 6 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total of 60 Gy delivered over 30 Days (approximately 6 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total of 60 Gy delivered over 30 Days (approximately 6 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total of 60 Gy delivered over 30 Days (approximately 6 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.